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A self-administered 11 item Vascular Access Specific Quality of Life Measure (VASQoL) was 
previously derived from detailed qualitative interviews with adult patients with kidney failure 
who have experienced vascular access using the Capabilities Approach as a theoretical base1. 
This study reports the psychometric validation of the VASQoL measure including its reliability, 
content validity and responsiveness to change.  
Methods 
Cognitive interviews were conducted with 23 adult patients with kidney failure after 
completion of the VASQoL measure. Focus group discussion with a vascular access 
professional multidisciplinary team was undertaken (n=8) and subsequently a further 101 
adult kidney failure patients with vascular access (TCVC, AVF or AVG) completed the digital 
VASQoL measure, EQ-5D and SF-36 questionnaires in a longitudinal study with prospectively 
recorded vascular access events. 
 Results 
Transcript analysis of cognitive interviews after VASQoL completion indicated that the content 
was comprehensive and well understood by participants. Assessment of Internal reliability for 
the VASQoL measure was high (Cronbach’s alpha 0.858). Test-retest reliability of the overall 
VASQoL measure was high (intra class correlation coefficient 0.916). In those patients who 
experienced a vascular access event, significant differences were observed in paired analysis 
of the VASQoL physical domain questions and vascular access function domain questions and 
in the EQ-5D usual activities, pain and anxiety domains. In those with no vascular access event, 
variation was observed in longitudinal analysis in VASQoL questions relating to worry about 
VA function and capability domains, whilst no variation was observed in the EQ5D measure. 
Conclusion 
The VASQoL measure has good internal consistency, test-retest reliability, convergent validity 
and responsiveness to change for clinically relevant vascular access outcomes. This provides a 
validated, vascular access specific quality of life measure that can be used in future trials of 
vascular access, evaluation of new technologies and routine use as a patient reported 




Creation and maintenance of vascular access (VA) for haemodialysis contributes significantly 
to the burden of hospital investigations, admissions and procedures for patients with kidney 
failure2. VA is complex as there are several modalities available (TCVC, AVF and AVG) that vary 
considerably in short and long-term outcomes and associated complications. A national 
appraisal of vascular access services using a mixed methods approach highlighted impact of 
vascular access creation and maintenance on patients and recommended that measurement 
of patient experience should be developed within vascular access services 3. Furthermore, 
there is widespread recognition that patient reported outcomes are important in engaging 
patients with chronic disease management and that capturing patients’ perceptions of their 
health and quality of life are important for research purposes, clinical monitoring, service 
improvement and national benchmarking 3-7.   
 
Although several general and disease specific quality of life (QoL) measures (SF-36, KDQOL-36, 
KDQOL-SF) have been used in relation to vascular access, this has mainly been on a cross 
sectional basis with comparison between vascular access type (AVG, AVF and TCVC) 8-12. The 
Kidney Disease QOL (KDQOL) measure is disease-specific with few items specifically related to 
vascular access 13. The Vascular Access Questionnaire (VAQ) was developed with a Canadian 
patient cohort initially as a measure of vascular access satisfaction rather than as a measure 
of quality of life. 14, 15 Similarly, when developing the Haemodialysis Access Related Quality of 
life instrument (HARQ), questions from existing health related QoL measures, previous studies 
and review articles were used to identify potential items that were then discussed in focus 
groups and initial cognitive assessment.16 In addition, the psychometric properties of HARQ 
have not been assessed16. The VAQ and HARQ questionnaires were both developed using 
themes derived from clinicians within multidisciplinary teams rather than patient perspectives 
as the initial, foundational building block of questionnaire development. Neither has been 
prospectively validated for responsiveness to vascular access events or complications.   
 
Recently the Kidney Health Initiative assembled an interdisciplinary work group to identify 
barriers to uptake of VA-specific PROMs17. They recommended the development of VA specific 
PROMs applicable to all VA-related interventions and populations and called for commitment 
to making the patient voice heard17-20. Indeed, the EMA and FDA have endorsed the use of 
validated patient reported outcome measures in clinical trials which assess the impact of 
interventions from the patient perspective 21, 22. However, given the lack of appropriately 
designed and validated measures, it is unsurprising that as few as 17% of trials in vascular 
access reported any patient reported outcomes and only 3% reported quality of life measures 
23. 
To address this, a pilot self-administered 11-item Vascular Access Specific Quality of Life 
Measure (VASQoL) was derived from detailed qualitative interviews with kidney disease 
patients using the Capabilities Approach as a theoretical base.1 The Capabilities Approach 
provides an alternative means to understanding wellbeing, based on a person’s capability or 
what a person is able to do 24. Nussbaum’s interpretation of the approach is based on the 
presupposition that one has the ‘capability’ to do, be, or have something. ‘Functionings’ are 
when these capabilities are realised24. Direct themes (physical feelings, VA function and 
anxiety) and Indirect themes (general enjoyment of health, relationships, autonomy and 
control, and everyday tasks) were derived from six scoping interviews and 18 detailed semi-
structured interviews. Further content analysis and revision were then undertaken through 
focus groups exploring patients and vascular access professionals’ perspectives, in order to 
derive an 11 item Vascular access specific quality of life (VASQoL) measure1. (Supp data) 
 
The aim of this study is to present the psychometric validation of the VASQoL measure 





The study protocol was approved by the London – Stanmore Research Ethics Committee Rec 
ref 19/LO/2005. NHSGGC Board approval was obtained (GN19RE634). Informed, written 
consent was obtained from all participants.  
The VASQoL measure was assessed for readability using the Flesch-Kincaid reading ease test, 
scoring 80.8, 71.1 and 79.2 for AVF, AVG and TCVC, and were interpreted as plain English and 
‘fairly’ easy to read. The study was undertaken in three phases (Table 1). 
The pilot version of the VASQoL measure contained 11 items that were self-completed 
electronically during an attendance at dialysis session or other healthcare appointment (Supp 
data).  Responses were recorded on a 10–point, end-anchored scale. No identifiable 
information was included in the VASQoL measure and the data were captured on a secure 
server of the University of Strathclyde.  
 
Recruitment 
Inclusion criteria were patients with chronic kidney disease stage 5 and who had undergone 
creation of VA, who underwent regular haemodialysis, and had the ability to give informed 
consent. Patients were recruited from 5 satellite haemodialysis units and the inpatient kidney 
unit in the West of Scotland. A quota sampling technique was used to ensure that key groups 
were represented in our Phase 1 sample (male vs female; diabetes vs no diabetes; AVF vs AVG 
vs TCVC; < 65y vs > 65 years; pre-dialysis vs < 1 year vs > 1 year; retired vs working vs not 
working; ethnicity) (Supp data Table 1.)25.  Recruitment continued until no new insights 
emerged. 
 
Phase 1 Cognitive interviews: to determine content validity 
Content validity assesses the extent to which the items in a questionnaire are representative 
of the theoretical construct through detailed cognitive interviews with patients 26, 27. Patients 
were asked to complete the VASQoL, SF-36 and EQ-5D questionnaires independently using a 
specifically designed patient portal application running on an encrypted tablet 28(Supp data 
Appendix 1). Participants then took part in a semi-structured interview to explore if the 
VASQoL questions were clear, understandable and relevant. Interviews were audio recorded 
and transcribed verbatim (Supp data appendix 2).  
 
Interview Analysis 
Interview data were analysed using Framework Analysis 29. All transcripts were checked for 
errors and during the familiarization process the transcripts were read and re–read, notes and 
comments added, and important or relevant statements highlighted. The interesting and 
meaningful passages were then labelled by question and domain. These codes were then 
transferred into an analytical framework, giving each domain descriptors. Following this, we 
allocated the labels to one of the initial 7 domains that were derived from the detailed 
qualitative interviews analysed through a capabilities approach1. 
In a final step these six themes and their subcategories were reduced to three domains after 
factor analysis:  physical, VA function and capabilities. Quotes for each subcategory were 
recorded. The option to suggest additional items and questions was presented to ensure 
important aspects were not missed. 
 
Phase 2 
Content validity was further assessed through review by a focus group of eight clinical 
professionals closely involved with delivery of VA and conducted by an experienced 
professional, non-clinical qualitative researcher (SG). Informed consent from the participants 
was obtained prior to the focus group.   Two authors ( KS and SR) analysed the interview 
transcripts using framework analysis and had further triangulation discussion with a third 
researcher (SG), who had performed the original derivation interviews from which the VASQOL 
questions were developed, regarding the domain descriptors and allocation of quotations.  
 
Phase 3 
The content-validated VASQoL measure was assessed in a longitudinal format in comparison 
with established health technology assessment quality of life measures (SF-36 and EQ-5D) 
over a six-week period (VASQoL and EQ-5D measures on weeks 1, 2, 4, and 6; SF-36 in weeks 
1 and 6). The SF 36 was only completed in the first and the last week of this period as the recall 
period for use of the SF36 is the preceding 4 weeks. A quota sampling technique was again 
employed. To detect significant differences in the temporal changes of quality of life in relation 
to vascular access events, we estimated a priori that at least 30% of the cohort would 
experience an access related event. Previous work utilising the VAQ measure identified a 25% 
event rate for radiological procedures alone in the preceding year 30. The sample size required 
for factor analysis in Phase 3 was determined by calculating a subject to item ratio of the 
VASQoL questionnaire (11 items) of 9:131. 
  
Responsiveness 
VASQoL and EQ-5D responsiveness in a known event cohort was assessed through this 
longitudinal format with prospectively recorded identification of objective vascular access 
events. Vascular Access Events were defined as:  Elective – a planned creation or revision of a 
vascular access including admission or attendance for insertion of a TCVC/ AVF or AVG or a 
routinely requested investigation of a VA (fistulogram) ; Urgent or Unexpected events 
included admissions for urgent (<24 hours notice) procedures ( fistulogram / thrombectomy) 
or salvage / revision operations or infection complications. Cannulation complications 
included in this study were those severe enough to require clinician (nephrology or surgeon) 
review or intervention (temporary VA or switch in VA). Cannulation problems or bruising that 
was not referred by the dialysis nurses for review was not recorded as a vascular access event 
in this study. We chose to define as elective and emergency/ unexpected for analysis as 
qualitative interview data highlighted the disruptive nature of vascular access events as a 
significant factor in patients’ quality of life. 
Data  
Anonymised data were abstracted to an SPSS database and linked to baseline characteristics 
(age, sex, Scottish Index of Multiple Deprivation (SIMD), diabetes mellitus, underlying kidney 
disease, time on kidney replacement therapy, time on haemodialysis and number of previous 
kidney transplants). Vascular access specific data included type (AVF/AVG/TCVC); localisation 
and side, and number of previous VA creations and revisions.  
Statistical analysis 
Statistical analyses were conducted using SPSS statistics v27 (IBM, USA). The cohort was 
initially analysed by population demographics to ensure representative quota sampling. 
Descriptive characteristics for each questionnaire item are reported as median +/- 
interquartile range (IQR) and as frequencies by questionnaire item.  
 
The distribution of responses for each item for the three questionnaires (VASQoL, EQ5D and 
SF36) were not normally distributed, therefore non-parametric analysis was undertaken. 
Paired data were analysed using the Wilcoxon signed rank test. Longitudinal data was 
compared using analysis of variance of repeated measures using the Friedman test.  Data were 
screened for univariate outliers prior to factor analysis. The minimum amount of data for 
factor analysis was satisfied with a final sample size of 101. The factorability of the 11 VASQOL 
items were examined using correlation, Kaiser-Meyer-Olkin measure of sampling adequacy 
and Bartlett’s test of sphericity.   
 
Internal consistency of the VASQoL measure and its factors was investigated with Cronbach’s 
alpha values. Test-retest reliability was assessed using the intraclass correlation coefficient 




Phase 1 Qualitative data 
26 patients were recruited to phase 1 (Supp data Table 1). Cognitive interviews were 
conducted after completion of the VASQOL, EQ-5D and SF-36 questionnaires. 23 patients 
completed the interviews. Analysis of these transcripts indicated that patients found the 
items, clear, relevant and important and did not have difficulty with the response options. In 
those cases, where we were unsure about the correct wording, we asked the patients to 
suggest alternatives to replace a specific word or sentence. Participants described the term 
‘worried’ rather than ‘concerned’ in the pilot questionnaire and this was replaced. No new 
items were identified in the cognitive interviews. Illustrative quotes by domain and question 
were analysed (Supp Table 2).  
 
Physical Domain 
Questions 1 to 3 relate to the physical domain of the measure, dealing with how a vascular 
access looks, how it feels during dialysis and whilst not on dialysis respectively. Appearance 
was described in terms of three different aspects: Firstly, a cosmetic aspect, which was more 
commonly mentioned by women; secondly whether it looked healthy or unhealthy; and 
thirdly a wider aspect of stigma ‘draws attention to being a kidney patient” (Patient 1).  
 The questions relating to how an access felt during dialysis and day to day confirmed the need 
for this distinction and was understood and relevant for different access types  
“Some days on dialysis are uncomfortable because of needling problems” (Patient 1) another 
said “if it’s not on my dialysis days … it’s not a problem (pain)” (Patient 21). Furthermore, the 
use of the word ‘feels’ was confirmed by patients as appropriate and they gave descriptions 
such as pain, aches, discomfort, itching and irritation from patients with all access types (Supp 
data Table 2). Almost all patients stated the importance of a working/ functioning access over 
a good appearance during interviews but also described appearance impacting across social 
activities and relationships. 
Vascular Access Function Domain 
The VA function domain assessed two sub-domains: loss of function (thrombosis) and 
problems or infection, assessed by question 4 and 5 respectively. Most of the patients stated 
the importance of a working/ functioning access and indicated that concerns about their 
vascular access accompany them day to day, independent of the current condition of the 
vascular access: “Being concerned is always on the back of my mind” (Patient 4).  This concern 
became foregrounded during vascular access events. These worries were even more relevant 
in patients who already experienced one or more failed vascular accesses: “I have run out of 
places, so it is important for me, that it keeps working” (Patient7). Beyond these thoughts 
were concerns about missing treatment strategies and alternative vascular access options in 
case of another access problem: “I am only concerned if it gets to the point where they can’t 
do anything about it” (Patient 9). Stable vascular access which was viewed as non-problematic 
was described as less concerning by patients: “Because I have had it so long, I don´t have any 
concerns of it stop working” (Patient 15). On the other hand, worry was present for those who 
had or were experiencing problematic access: “No problems day to day but I depend on my 
access...I am concerned when they have a problem on dialysis” (Patient 22). 
 
Capabilities Domain 
The capabilities domain included the subdomains enjoyment, relationships, hobbies, tasks or 
work. Question 6 asked if their VA interfered with enjoyment.  A frequent statement was that 
it was not the vascular access itself that limited them, but the time-consuming aspect, and 
side-effects of dialysis, which led to reduced positive activities. However, participants were 
able to separate out the aspects of their life that were impacted by their vascular access and 
those related to kidney failure in general. 
“The days I am not on dialysis I am not going out...I am really just sitting at home…I wouldn´t 
say, it’s the line, it´s just my mobility and general feeling tired...If I had been a lot fitter, my 
fistula wouldn´t have very much limited me in doing things” (Patient 5).   
 
The impact of VA on relationships varied significantly.  The relationships subdomain was most 
frequently interpreted as relationships with friends and wider family and VA impact responses 
varied from not impacting at all “People that I value don’t see my fistula. They don’t care that 
I have got it” (Patient 10) to significant impact “It affects your relationship, if you are self – 
conscious of your body image” (Patient 2). However, more intimate relationships also were 
discussed as being affected, If I lie close to my wife, she feels the pulse and can hear it; she 
freaks out (Patients 6) or “my husband is terrified to give me a hug because of the line” (Patient 
12).   
Question 10 about interference with social activities led to a wide range of answers ranging 
from little interference “When I am at home, I am still able to read and watch TV; it hasn’t 
stop enjoying my days at home in between” (Patient 11) to significant interference “Its 
everyday silly things, how to lie, when you are sleeping, lifting the grandchildren” (Patient 7) 
or “It has interfered with things I enjoy, because I used to love cooking “(Patient 10)  
Furthermore, this question also stimulated patients to disclose the disruptive nature of loss of 
VA function on wider aspects of their lives “Usually my graft never interferes with what I try 
to do… but in the last week it has been because it clotted” (Patient 9). Participants  
described activities that were important to them demonstrating that the question was 
understood to apply to their preferences of activity in their context suggesting that the 
questions captured the specific impact for that individual. Similarly, in question 11 about work, 
tasks or studying specific actions were discussed suggesting that the questions prompted 
thoughts that were relevant to the patients’ situation. “I can´t hold a pen any length of time 
and my hands cramp and I get in pain” (Patient 10) “For some professions... it has 
significance...but not now I'm retired (Patient 4) and “I can still do work in the house and I can 
lift bags... It doesn’t affect me doing tasks really” (Patient 20) 
 
Shared Decision-making  
When asked about whether they felt involved in decisions about the care of their access (Q9) 
participants related this to responsibility for the vascular access and involvement in decisions 
on treatment and care by health professionals. Often this involved practical examination and 
interventions.  “It is important to have the option of being interested and that you are told 
[physically], what is going to happen” (Patient 5).  This was often related to how this was 
discussed, cannulated and assessed by nursing staff in the dialysis unit “basically decisions 
with the nurses, checking it and things like that “(Patient 20) but also covered decisions about 
access modalities “I have the final say to whether I am getting a graft or a fistula or a line... I 
am always included” (Patient 17). 
  
Phase 2 Focus Group  
A multidisciplinary focus group, detailed in Table 1 subsequently undertook a semi-structured 
discussion led by an experienced qualitative researcher (SG) (Supp data Table 3). The focus 
group identified similar themes in the physical domain questions 1 to 3 only additonally 
mentioning concerns about ‘at risk’ fistulas or grafts. Professionals focused more on quality of 
VA function and  quality of dialysis over the long term, compared to patients who were more 
likely to describe their vascular access as ‘problematic’. The professional focus group felt that 
the questions regarding enjoyment and interference with hobbies or social activities were 
similar but allowed patients to answer for their specific situation.  
Interestingly, in item 9 (‘In the last week I feel I have been included in decisions about the care 
of my line / fistula / graft’) the VA professionals focused on whether the ‘decisions’ related to 
VA  were ‘micro decisions’ (day-to-day cannulations) or ‘macro decisions’ (modality choice -
Line AVF AVG). In comparison, patients, acknowledging the need for decisions, more often 
commented on  feelings of inclusion, autonomy and discussion about decisions. Professionals 
discussed different ‘tasks’ and suggested more specificity for question 11, but felt that it 
conveyed the necessity of general life for most patients. No new items were generated from 
the focus group discussions therefore no further groups were convened. 
 
Phase 3. Quantitative Validation 
101 patients were recruited to complete the VASQOL, EQ5D and SF36 questionnaires in a 
hospital-based setting over a 6 week period (Table 2). All item scores in the VASQoL measure, 
EQ5D 5L and SF36 summary components failed a Shapiro-Wilk test of normality, and thus 
results are presented as median and interquartile range (IQR). The ceiling effect in each 
questionnaire data set was significant ranging from 24-54.5% in EQ5D items and 26-50% in 
VASQoL items. The SF36 raw scores for 8 scales were transformed and are reported using the 
sub scales 32, 33 : Physical Functioning, Bodily Pain, General Health, Vitality, Social Functioning, 
Role Emotional and Mental Health Role (Table 3). 
 
Factor analysis 
Factorability of the 11 VASQoL items was examined. Firstly, it was observed that 11 of the 11 
items correlated at least 0.3 with at least one other item, suggesting reasonable factorability. 
Secondly, the Kaiser-Meyer-Olkin measure of sampling adequacy was 0.804, above the 
recommended value of 0.6, and Bartlett’s test of sphericity was significant (χ2 = 522.649, p < 
.000). Finally, the communalities were all above 0.3, confirming that each item shared some 
common variance with other items. Given these overall indicators, factor analysis was deemed 
to be suitable with all 11 items.  
Principal components analysis was used because the primary purpose was to identify the 
factors underlying the VASQoL measure. Initial eigenvalues indicated that the first three 
factors explained 44.5%, 12.9 %, and 9.1% of the variance respectively. Solutions for three 
factors were examined using varimax rotation of the factor loading matrix. The three factor 
solution, which explained 66.5% of the variance, was preferred because of its previous 
theoretical support and the levelling off of eigenvalues on the scree plot after three factors. A 
varimax rotation provided the best defined factor structure. All items in this analysis had 
primary loadings over 0.5 and no items had a cross loading of >0.4 (Supp Table 4). The items 
which loaded onto the three factors could be theoretically justified and were described as 
Physical, VA function and Capability factors. The factor labels proposed by the theoretical basis 
suited the extracted factors and were retained. 
Reliability 
Internal reliability for the 11 item VASQoL measure was investigated by Cronbach’s alpha 
values. Cronbach’s alpha was 0.858 which indicates a high level of internal consistency. No 
substantial increases in alpha would have been achieved by elimination of items (questions). 
Internal consistency for each of the factor identified was further examined using Cronbach’s 
alpha. The Cronbach’s alpha coefficients for the 3 factors were good: 0.707 for the Physical 
Factor (4 items), 0.719 for the Function Factor (3 items), and 0.867 for the Capability Factor (4 
items). Test-retest reliability of the overall VASQoL measure using intra class correlation 
coefficient one week apart (excluding participants with reported vascular access events) using 
a two-way mixed effects absolute agreement model was 0.916 (95% CI 0.87-0.946 ) indicating 
excellent stability.  
Responsiveness analysis  
VA-related events were prospectively recorded at the time of questionnaire completion. 
There were 36 vascular access events in 32 patients, during the 6 week study period (Supp 
Table 2). 26 of these events were unexpected events, whilst 10 were elective vascular access 
events. Paired analysis of data collected at, or within 1 week of an event, was compared. For 
the SF36 questionnaire analysis was performed using events within 1 month of completion. 
Significant differences were observed in the VASQoL physical domain questions (‘looks’ and 
‘how it feels’ ) and VA function domain questions and by the EQ5D measure in the ‘usual 
activities’, ‘pain’ and ‘anxiety’ domains in the vascular access event cohort. (Table 4)  
When analysed by events coded as ‘emergency or unexpected’ additional differences were 
observed across the capability domains. These included interference with work, study or tasks, 
interference with hobbies or social activities, vascular access limiting enjoyment, as well as 
the VA function and physical domains. (Table 5) 
VASQoL and EQ5D data from those participants who had complete data and were stable 
during the study period were also compared using non-parametric analysis of variance. In this 
non-event cohort, variation in the VASQoL measure over a 6 week period was observed only  
in questions relating to ‘worry about VA function’ and ‘capability’ domains. No variation was 
observed in the EQ5D measure in any domain (Table 6).  Whilst the EQ5D measure is 
sufficiently sensitive to detect changes in health status and major functional deterioration 
during emergency or urgent events (Table 5), the VASQoL measure was more sensitive to 
interference in hobbies and social activities , tasks  or work that patients undertake.  The 
VASQoL measure also captured changes in the anxiety associated with vascular access 
function that was not identifed by anxiety domains in generic quality of life measures. (Table 
6). No differences were observed in the paired SF36 summary scores in patients who 
experienced vascular access events. This may be due to the longer period of time (1 month) 
that the SF36 utilises and potentially reduces it sensitivity. However, by using objectively 
defined VA event measures in this prospective study we sought to limit this potential recall 





The lack of validated patient reported outcome measures specific to vascular access is now 
well recognized, and limits not only current practice, but also future trials 23, 34, 35. The list of 
pre-requisites for such measures is long and demanding: they must be based on appropriate 
theoretical models, have content validity, be validated in a longitudinal setting, be sensitive 
to clinical events relevant to objective vascular access end points and also be sensitive to the 
patient experience that may not be routinely reported to vascular access care providers. This 
disease-specific sensitivity is a known limitation of generic preference-based measures of 
quality of life such as EQ-5D and SF-36. Despite this lack of sensitivity they are routinely used 
for health economic analysis and because of the significant costs associated with vascular 
access creation and maintenance it is the main reason we chose these as initial comparators 
for the VASQoL measure to validate this for effective mapping of health economic data in the 
future.   
We have shown that the VASQoL meets these demands, and is thus a valid instrument to 
measure vascular access specific quality of life in patients with kidney failure. Psychometric 
testing has confirmed the VASQoL measure to be robust, reliable, valid and responsive to 
clinically relevant changes. 
 
Previous work in this field has sought to measure patient-reported views of access-related 
problems to understand the use of lines among kidney failure patients15. The revised Short 
Form – Vascular Access Questionnaire (SF-VAQ) focused on four areas: satisfaction with access 
modality; experience of physical symptoms, such as pain or bleeding; consideration of access 
and social functioning; and experience of dialysis complications 14. Intravenous needle 
cannulation of fistula and grafts were considered as a ‘major source of dissatisfaction,’ leading 
Kosa to argue for the development of strategies to mitigate patient’s fear and pain linked to 
cannulation 14, 36. The SF- VAQ has also been used in cross-sectional cohort studies in Canada, 
America (n=77 patients) and the UK (n=749) of prevalent haemodialysis patients to correlate 
patient characteristics and VA modality differences with VAQ scores 30, 36, 37. However, work 
to establish its use in frequency of measurement and responsiveness to change during 
prospectively recorded events has not been undertaken. The development of the HARQ 
instrument identified six domains during focus group discussion relating to physical function, 
emotional impact, physical symptoms, sleep, social role/function and healthcare 
interactions16. Strikingly ‘worry or anxiety’ in relation to vascular access was mentioned twice 
as many times as all other domains and this was also a dominant theme in the qualitative 
analysis of the VASQoL derivation work and is reflected in the VASQoL measure which noted 
variation in questions 3 and 4, over a 6 week period even in the absence of an objective VA 
event1.  
This is the first study to demonstrate a vascular access specific quality of life measure that 
demonstrates responsiveness to change in QoL domains associated with vascular access 
events in a paired analysis. Furthermore, the VASQoL measure demonstrated variation in 
responses across the 6-week study period (not observed in 1-week test-retest reliability) in 
the absence of VA events in those questions which described worry about loss of VA function, 
interference with relationships, interference with hobbies / social activities, interference with 
work or tasks and involvement in decisions about care of their access. This is consistent with 
the wider qualitative literature which reports the significant effects of vascular access creation 
and maintenance, which included anxiety and worry about failure of VA, impingement on way 
of life, family tension and concern about cannulation and unfamiliar providers 34. The VASQoL 
items are entirely consistent with the recent summary of patient reported impacts and PRO 
domains of importance highlighted by the recent KHI vascular access PROMS workgroup17.  
 
VA function has been identified as the most critically importance outcome in vascular access 
trials by the SONG collaboration. Six themes were identified based on comments from all 
stakeholder groups that reflected the reasons behind the ratings of importance of vascular 
access outcomes: necessity for HD (function), applicability across the vascular access types, 
frequency and severity of debilitation, minimizing hospitalisation, optimising technical 
competence (use or care of VA) and direct impacts on appearance and lifestyle35. These 
themes are reflected in the items developed within the VASQoL measure.   
 
The VASQoL measure was derived from the patient perspective and patient rankings at focus 
groups (rather than professional ranking of themes) were given primacy in its development1. 
Such nuanced findings with corroboration from cognitive interviews in this validation study is 
reassuring that it measures aspects of quality of life important to kidney patients that are not 
solely identified by objective vascular access events such as loss of patency. Importantly the 
VASQoL is not simply an amalgamated overall score with variations detected between 
patients, rather it should be seen as descriptive pattern of the influence of VA use and events 
on the different domains of QoL. 
 
This study recruited patients from the West of Scotland with an age, primary kidney disease, 
vascular access history and mix of vascular access modalities that is representative of the UK 
population due to an intentional quota sampling technique, however black and minority 
ethnic groups although included, were less well represented and further validation work is 
required to understand if the VASQoL measure is sensitive in other populations. Additional 
translations are planned to allow validation studies in Europe to proceed. The presence of a 
ceiling effect in the VASQoL, EQ5D and in some domains of the SF36 is significant, although 
this may reflect the cohort studied as it is recognised that haemodialysis patients are a 
population who undergo a heavy treatment burden in establishing or maintaining vascular 
access. The ceiling effects observed are a potential limitation of a measure, as the presence of 
such an effect may limit its discriminatory value. Despite this, the VASQoL measure was 
associated with changes in keeping with what would be expected with a known group and was 
also sensitive to change over time. Further refinement of the VASQoL measure with anchored 
Likert scaling is underway to optimise the utility and analysability of VASQoL as is comparative 
work with the KD-HRQOL measure within the Anaesthesia Choice for Creation of 
Arteriovenous Fistulae Study (NIHR-HTA 130567). 
 
The burden of completion of patient reported outcome measures has also been highlighted 
as a potential barrier to their use.17 The 11 point VASQoL measure has also been assessed in 
parallel work for its usability with excellent patient feedback but highlighting the 
need for ongoing work to improve accessibility particularly for those with limited vision.38 
The validation of the VASQoL measure reported in this paper now offers the opportunity to 
assess patient reported outcomes alongside traditional VA trial endpoints in the knowledge 















Table 2. Demographics of the Longitudinal Study Cohort 
AVF- arteriovenous fistula, AVG -arteriovenous graft, TCVC -Tunnelled central venous catheter, SIMD -Scottish 
Index of Multiple Deprivation, VA- vascular access, HD Haemodialysis, RRT – renal replacement therapy,  PD- 
Peritoneal Dialysis,  Tx- Transplant 
Phase 1  
 
Questionnaire Pilot and 
Cognitive interviews 
 
January 2020- May 2020 
Phase 2  
 









June 2020 - November 2020 
34 approached 
• 6 declined 
• 2 visual impairment 
10 approached 135 approached 
 
26 recruited  8 recruited 101 recruited 
23 completed  
VASQoL, EQ-5D and SF36 
 
Semi-structured interview 
• 1 withdrew 
• 2 unable to 




1 Vascular access surgeon  
1 Interventional 
radiologist,  
2 Vascular access nurse 
specialist  
1 Haemodialysis nurse 
Questionnaires completed 
 
VASQoL + EQ-5D  
           weeks 1,2,4 and 6 
SF-36 weeks 1 and 6 
 







(n = 101) 
AVF 
(n = 57) 
AVG 
(n = 16) 
TCVC 
(n = 28) 
Age (mean ± SD) 58.7 (±14.1) 59.1 (±14.3) 59.5 (±16.1) 57.3 (±19.5) 
SIMD, n (%) 
     1 (most deprived) 
     2 
     3 
     4    





















































































































































































2 (7.1 ) 
Time on VA (days)  






(35 – 898) 
224 
(16-529) 
Time on HD (days)  
  median (IQR) 
607 
(157 – 1460) 
583 




(60 – 933) 
Time on RRT (days)  
  median (IQR) 
737 
(277 – 2140) 
693 





Time on PD (months)  
mean (± SD) 
2.9 (± 8.0) 2.1 (± 7.3) 3.4 (± 9.5) 4.4 (±8.6) 
Time on HD, n (%) 
< 1 year 

































Table 3. Longitudinal Analysis: Descriptive Results By Measure and Week  
 Week 1 (n=101) Week 2 (n=88) Week 4 (n=91) Week 6 (n=91) 
 Median  CE % Median CE % Median CE % Median CE % 
VASQoL 









Q2 ‘feels during dialysis’ 10  
(8-10) 




42.6 9  
(8-10) 
40.6 
Q3 ‘feels day to day’ 9 
(8-10) 
44.6 9  
8-10) 
40.6 9  
(7.2-10) 
41.6 9  
(7-10) 
38.6 
Q4 ‘access stopping working’ 9  
(5-10) 
48.5 9  
(6-10) 












45.5 10  
(8-10) 
49.5 10  
(6-10) 
48.5 
Q6 ‘access limits enjoyment’ 9  
(6-10) 
47.5 8  
(5-10) 





Q7 ‘access has got in the way 





47.5 9.5  
(7-10) 
45.5 10  
(6-10) 
46.5 




25.7 8  
(4-9) 
17.8 7  
(6-9) 
17.8 8  
(5-9) 
14.9 
Q9 ‘included in decisions about 
care of access 
8  
(3-10) 
34.7 8  
(5-10) 
24.8 8  
(6-10) 
29.7 8  
(5-10) 
35.2 
Q10 ‘Interference with 
hobbies / social activities’ 
9  
(7-10) 
48.5 9  
(5-10) 
33.7 9  
(5-10) 
36.6 9  
(4-10) 
35.6 








33.7 9  
(5-10) 
35.6 









EQ5D         
‘walking’ 4  
(2-4) 
23.8 3  
(3-4) 
16.8 4  
(3-5) 

























































2.2 54  
(44-75) 
1.1 
SF 36         
Physical Function 30  
(15-65) 
1 - - - - 30  
(15-55) 
3 
Physical Role 25  
(0-75) 










General Health 32  
(20-47) 
























Mental Health 64  
(50-84) 
5.9 - - - - 64  
(52-84) 
5.5 
Key: VASQoL + EQ5D - raw scores. SF 36 - transformed across 8 sub-domains; median (interquartile range) + percentage ceiling.  








VASQoL (n=36)     





     





     





     





     





     





     





     





     





     





     





     






     





     





     





     










Table 5. VASQOL And EQ5D item Scores: stable state vs. emergency vascular access event  



























VASQoL (n=26)     





     
Q2 ‘feels during HD’ 10  




     





     





     





     





     






     





     
Q9 ‘decisions about care of access’ 8 
(5- 10) 
6 
(3.75 – 9.25) 
-1.354 0.176 
     





     
Q11 ‘interference with work/study/tasks’ 9 
(5.75-10) 
6 
(2.75 – 10) 
-2.181 0.029* 
     
EQ5D (n=25)     





     





     





     





     





     
EQ5D Health Score 60.5 
(40.5-84.25) 
51.5 
(40.5 – 75) 
-1.279 0.201 
Table 6. VASQoL and EQ-5D measured by week in the stable cohort.  
 
 Week 1 Week 2 Week 4 Week 6 Chi-Sq p value 
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Non – Parametric ANOVA using Friedman Test (n=61 – completed all 4 weeks) 
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